About This Guide

This guide provides essential information for parents navigating pregnancy with maternal alloimmunization, a condition where maternal antibodies can cross the placenta and cause Hemolytic Disease of the Fetus and Newborn (HDFN).

Key Areas Covered:

How Sensitization Happens: The guide explains how maternal antibodies develop, most often from a previous pregnancy, miscarriage, trauma, or transfusion. In some cases, the cause is unknown.

Determining Baby’s Risk: Testing can include father’s antigen status and zygosity, cell-free fetal DNA (cffDNA) testing, or (less commonly) amniocentesis. These help determine if the baby carries the antigen targeted by maternal antibodies.

Antibody Titers: Titers measure the activity of maternal antibodies. A level of 16 or higher is usually considered critical, triggering more intensive monitoring. Anti-Kell and cases with prior affected pregnancies require special handling as titers aren’t reliable indicators. Recommended schedule: every 4 weeks until 26 weeks, then every 2 weeks until delivery.

Monitoring for Fetal Anemia: Once titers reach critical, weekly MCA Doppler ultrasounds are used to assess for fetal anemia. Readings above 1.5 MoM may indicate moderate to severe anemia and the possible need for an intrauterine transfusion (IUT). Parents are encouraged to ask about PSV results and their provider’s IUT experience.

Treatment Options: If anemia develops, intrauterine transfusions can be performed, usually through the umbilical cord. Risks are low when done by experienced specialists, though multiple transfusions may be needed every 2 weeks until delivery. For severe or early cases, IVIG or plasmapheresis may be used to slow the antibody attack as early as 12–14 weeks.

Antenatal Testing: Beginning around 32 weeks, additional testing such as non-stress tests (NST) and biophysical profiles (BPP) are recommended to monitor baby’s well-being and guide safe timing of delivery.

Important Considerations: Success rates are high with proper monitoring and experienced care. The guide emphasizes the importance of having an MFM team familiar with alloimmunization and a clear follow-up plan for both pregnancy and postnatal care.